Abstract
Of 25 patients who entered a year-long doubl-blind comparison study of high (12 mg/day) versus low (3 mg/day) dosages of ergot mesylated (Hydergine), 17 completed the full yera of study and no patiens suffered problematic side-effects. On a number of complex tests of memory function, there was no difference between the patients receiving low-dose versus high-dose Hydergine. There were also no significant between-group differences in recognition memory, incidental memory, naming ability, figure drawing, mood or other psychiatric symptoms. These data confirm that Hydergine is safe and that trials in a low dosage range may suffice.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 375-380 |
| Number of pages | 6 |
| Journal | International Journal of Geriatric Psychiatry |
| Volume | 5 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1990 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Geriatrics and Gerontology
- Psychiatry and Mental health
Cite this
ERgot mesylates for Alzheimer's disease : A year-long double-blind trial of 3 mg VS 12 mg daily. / Jenike, M. A.; Albert, Marilyn; Baer, L.; Gunther, J.; Corvino, C.
In: International Journal of Geriatric Psychiatry, Vol. 5, No. 6, 1990, p. 375-380.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - ERgot mesylates for Alzheimer's disease
T2 - A year-long double-blind trial of 3 mg VS 12 mg daily
AU - Jenike, M. A.
AU - Albert, Marilyn
AU - Baer, L.
AU - Gunther, J.
AU - Corvino, C.
PY - 1990
Y1 - 1990
N2 - Of 25 patients who entered a year-long doubl-blind comparison study of high (12 mg/day) versus low (3 mg/day) dosages of ergot mesylated (Hydergine), 17 completed the full yera of study and no patiens suffered problematic side-effects. On a number of complex tests of memory function, there was no difference between the patients receiving low-dose versus high-dose Hydergine. There were also no significant between-group differences in recognition memory, incidental memory, naming ability, figure drawing, mood or other psychiatric symptoms. These data confirm that Hydergine is safe and that trials in a low dosage range may suffice.
AB - Of 25 patients who entered a year-long doubl-blind comparison study of high (12 mg/day) versus low (3 mg/day) dosages of ergot mesylated (Hydergine), 17 completed the full yera of study and no patiens suffered problematic side-effects. On a number of complex tests of memory function, there was no difference between the patients receiving low-dose versus high-dose Hydergine. There were also no significant between-group differences in recognition memory, incidental memory, naming ability, figure drawing, mood or other psychiatric symptoms. These data confirm that Hydergine is safe and that trials in a low dosage range may suffice.
UR - http://www.scopus.com/inward/record.url?scp=0025204662&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025204662&partnerID=8YFLogxK
U2 - 10.1002/gps.930050605
DO - 10.1002/gps.930050605
M3 - Article
AN - SCOPUS:0025204662
VL - 5
SP - 375
EP - 380
JO - International Journal of Geriatric Psychiatry
JF - International Journal of Geriatric Psychiatry
SN - 0885-6230
IS - 6
ER -